RE:RE:RE:RE:RE:Another New Job Posting: Paralegal, Corporate & SecuritiesExtra 10's of millions to bring to market. It shouldn't have been that much to market Ryplazim as most of the work had alreday been done. They had under 2,000 patients in the USA and not supplying the world market yet.
The value was not in Ryplazim and the plasminogin indication. It was future indications like reducing diabetic amputations, burn victims, eye and ear issues, etc.
Consonance saw the writing on wall from the BOD meetings. LMNL was not trying to make it work, sold the assets for next to nothing and have nothing left.
Thomvest does however get to claim the $100's of millions in write downs and losses and retain 4050 as it is collateral on the loans. Remember LMNL is a subsidary of Thomvest. Very different from just owning shares. Some here just don't understand this and the how clever TV has been.
hankman wrote: You posted: "hey figured that the return on Ryplazim was not worth the extra 10’s of millions (??) to bring it to market. This could also explain why Consonance jumped ship."
So what happened in the short time from when they convinced Consonance to invest in the recapitalization until the short while later when Consonance sold out at a loss? Did that much change over that short time? They were in full control and in the drivers seat. SO WHAT WENT WRONG??